ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced on January 22, 2024 the appointment of Thomas J. DesRosier, Esq. (’80) to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.
Thomas J. DesRosier, Esq. joins ARIAD as executive vice president, chief legal and administration officer, and secretary.
Mr. DesRosier has more than 30 years of global biotechnology and pharmaceutical industry experience and joins ARIAD from Cubist Pharmaceuticals, Inc., where he held the same position as the one he will assume at ARIAD. Prior to Cubist, Mr. DesRosier was senior vice president, general counsel, North America of Sanofi, a position he assumed following the acquisition of Genzyme Corporation by Sanofi in 2011, where he had served as Genzyme’s senior vice president, chief legal officer.
“Mr. DesRosier is a talented and experienced attorney, who has had a stellar career in the pharmaceutical and biotechnology industries,” stated Dr. Berger. “We are excited to welome Tom to ARIAD, and I look forward to working closely with him as we make the transition to a profitable oncology company over the next three years. I expect Tom to have a positive impact on the Company in many areas immediately upon joining our leadership team.”
Prior to his 12-year tenure at Genzyme, Mr. DesRosier held a number of senior legal positions at Wyeth Pharmaceuticals, Genetics Institute, and E.I. DuPont de Nemours. He received his J.D. from Wake Forest University School of Law and his B.A. degree in Chemistry from the University of Vermont.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.